Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 1, 2006, Pages 39-48

  Sanders, Andrew J ^a   Parr, Christian ^a   Davies, Gaynor ^a   Martin, Tracey A ^a   Lane, Jane ^a   Mason, Malcolm D ^b   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Hepatocyte Growth factor; HGF; Matriptase 1; Prostate cancer; TTSP

Indexed keywords

MATRIPTASE 1; PROTEIN INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 2; RIBOZYME; SCATTER FACTOR; SERINE PROTEINASE; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RIBOZYME THERAPY; STATISTICAL SIGNIFICANCE;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PHENOTYPE; PROSTATIC NEOPLASMS; RNA, CATALYTIC; SERINE ENDOPEPTIDASES;

EID: 33846076709     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases: Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 276: 857-60, 2001.
2. Lung JC, Schuller DE. Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br J Cancer 84: 237-43, 2001.
3. Lee JW, Song SY, Choi JJ, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY. Dickson RB. Bue DS. Increased expression of mulriptuse is associated with histopathologic grades of cervical neoplasia. Mum Pathol 36: 626-33, 2005.
4. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Wulson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692-96, 2001.
5. Mori Y, Kono K, Matsumoto Y, Fujii H, Yamane T, Mitsumata M, Chen WT. The expression of a type II transmembrane serine protease (seprase) in human gastric carcinoma. Oncology 67: 411-9, 2004.
6. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, Antalis TM. Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 22: 237-58, 2003.
7. Wallrapp C, Hähnel S, Müller-Pillasch F, Burghardt B, Iwamura T, Ruthenbürger M, Lereh MM, Adler G, Gress TM. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res 60: 2602-6, 2000.
8. Hoang CD, D'Cunha J, Kratzke MG, Casmey CE, Frizelle SP, Maddaus MA, Kratzke RA. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125: 1843-52, 2004.
9. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiling in primary ovarian serons papillary tumours and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112; 14-25, 2004.
10. Shi YE, Torri J, Yieh L, Wellstein A, Lippman MB, Dickson RB. Identification anil characterisation of a novel matrixdegrading protease from hormone-dependent human breast cancer cells. Cancer Res 53: 1409-15, 1993.
11. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a kunitz-types serine protease inhibitor from human milk. J Biol Chem 274: 18237-42, 1999.
12. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noneatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 278: 26773-79, 2003.
13. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease I and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogcn activator as substrates. J Biol Chem 275: 26333-42, 2000.
14. Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY. Characterization of matritpase expression in normal human tissues. J Histochem Cytochem 51: 1017-25, 2003.
15. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W. Engelholm LH. Behrendt N. Bugge TH. Matriptase/MTSP-I is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21: 3765-79, 2002.
16. List K, Szabo R, Molinalo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS, Bugge TH. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 19: 1934-50, 2005
17. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase. an epithelial membrane serine protease. J Biol Chem 275: 36720-25, 2000.
18. Jiang WG, Davies G, Podstad O, Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-? connection. Biochem Biophys Res Commun 330: 253-62, 2005.
19. Jiang WG, Grimshaw D, Lane J, Martin TA, Abounder R, Laterra J, Mansel RE. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clinical Cancer Res 7: 2555-62, 2001.
20. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K, Mansel RE, Targeting matrilysin and its impact on tumour growth in vivo: the potential implications in breast cancer therapy. Clinical Cancer Rex 11: 6012-19, 2005.
21. Jiang WG, Hiscox S, Hallett MB, Horrohin DF, Mansel RE, Puntis MCA. Regulation of the expression of E-cadherin on human cancer cells by gamma linolenic acid. Cancer Res 55: 5043-48, 1995.
22. Jiang WG, Hiscox S, Hallett MB, Horrohin DF, Scott C, Puntis MCA. Inhibition of invasion and motility of human colon cancer cells by gamma linolenic acid. Br J Cancer 71: 744-52, 1995.
23. Jiang WG, Hiscox S, Parr C, Martin TA, Matsumoto K, Nakamura T, Mansel RE. Antagonistic effects of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Cancer Res 5: 3695-3703. 1995.
24. Martin TA, Parr C, Davies G, Watkins G, Lane J, Matsumoto K, Nakamura T, Mansel RE, Jiang WG. Growth and angiogenesis ol human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24: 1317-23, 2003.
25. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor I in the progression of node-negative breast cancer. Cancer Res 63: 1101-5, 2003.
26. Tanimoto H, Shigemasa K, Tian X, Gu L, Beard JB, Sawasaki T, O'Brien TJ. Transmembrane serine protease TADG-15 (ST14/Matritptase/MTSP-1): expression and prognostic value in ovarian cancer. Br J Cancer 92: 278-283, 2005.
27. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumour clinicopathological parameters. Clinical Cancer Rex 8: 1101-7, 2002.
28. Satomi S, Yamasaki Y, Tsuzuki S, Hitomi Y, Iwanaga T, Fushiki T. A role for Membrane-Type Serine Protease (MTSP-1) in intestinal epithelial turnover. Biochem Biophys Rex Commun 287: 995-1002, 2001.
29. Förbs D, Thiel S, Stella MC, Stürzebecher A, Schweinitz A. Steinmetzer T, Stürzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinomas. Int J Oncol 27: 1061-70, 2005.
30. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, Agus DB, CVS-3983. a selective matriptase inhibitor suppresses the growth of androgen independent prostate tumour xenografts. Prostate 61: 228-35, 2004.